128 related articles for article (PubMed ID: 18083399)
1. Dabigatran versus enoxaparin after total hip replacement.
Martins HS; Scalabrini-Neto A; Velasco IT
Lancet; 2007 Dec; 370(9604):2002-3; author reply 2003-4. PubMed ID: 18083399
[No Abstract] [Full Text] [Related]
2. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Wolowacz SE; Roskell NS; Plumb JM; Clemens A; Noack H; Robinson PA; Dolan G; Brenkel IJ
Thromb Haemost; 2010 Feb; 103(2):360-71. PubMed ID: 20024501
[TBL] [Abstract][Full Text] [Related]
5. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Plumb JM; Clemens A; Monz BU
Pharmacoeconomics; 2010; 28(9):781-2; author reply 782-4, 784-5. PubMed ID: 20824908
[No Abstract] [Full Text] [Related]
7. Dabigatran etexilate for prevention of venous thromboembolism.
Eikelboom JE; Weitz JI
Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
[TBL] [Abstract][Full Text] [Related]
9. [Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement].
Bouée S; Zufferey P; Fagnani F
Therapie; 2009; 64(4):249-57. PubMed ID: 19804705
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
11. Trials of venous thromboembolism prevention.
Norrie J
Lancet; 2007 Sep; 370(9591):915-7. PubMed ID: 17869620
[No Abstract] [Full Text] [Related]
12. [Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].
Omel'ianovskiĭ VV; Zagorodniĭ NV; Margieva AV; Tsfasman FM
Khirurgiia (Mosk); 2010; (5):72-81. PubMed ID: 20568660
[No Abstract] [Full Text] [Related]
13. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
16. [Thrombin inhibitor shows stable safety profile in the practice].
MMW Fortschr Med; 2008 Dec; 150(51-52):38-9. PubMed ID: 19149309
[No Abstract] [Full Text] [Related]
17. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran etexilate.
Eriksson BI; Smith H; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2008 Jul; 7(7):557-8. PubMed ID: 18591978
[No Abstract] [Full Text] [Related]
19. New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Verma AK
ANZ J Surg; 2009 Nov; 79(11):773-4. PubMed ID: 20078521
[No Abstract] [Full Text] [Related]
20. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
